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Conducting drug discovery efforts in patient- and disease-specific cells can maximize their likelihood of
success. In this issue of Cell Stem Cell, Yang et al. (2013) demonstrate the power of lineage-specific cell-
based drug screens by identifying a compound that promotes survival of stem-cell-derived ALS mutant
motor neurons.Amyotrophic lateral sclerosis (ALS), more
commonly known as Lou Gehrig’s dis-
ease, is a notoriously intractable neuro-
degenerative disorder involving specific
loss of motor neurons (MNs). As a result,
patients suffer progressive paralysis and
die due to loss of respiratory function
(Maragakis, 2010; Robberecht and
Philips, 2013). Causative mutations in
superoxide dismutase-1 (SOD1) are
found in 20% of inherited-ALS patients
(Robberecht and Philips, 2013). Currently,
the only FDA-approved drug for treat-
ment of ALS is Riluzole, which has
merely modest effects, extending patient
lifespan by several months. Efforts to
find more effective drugs have yielded
two promising compounds, olesoxime
and dexpramipexole, but the results of
recent clinical trials were not promising
(Cudkowicz et al., 2011; Robberecht and
Philips, 2013).
One of the major obstacles in study-
ing neurodegenerative diseases is the
difficulty of obtaining relevant cell types
for analysis. In the case of ALS, MNs
are at the root of disease pathophy-
siology. Unfortunately, culturing MNs
is very difficult, and it is almost im-
possible to biopsy sufficient numbers of
MNs from patients for extensive study
(Maragakis, 2010). Recent progress in
stem cell biology, especially the develop-
ment of induced pluripotent stem cell
(iPSC) technology, provides immense
opportunities for modeling human dis-
ease and screening potential thera-
peutics, using disease-relevant cell
populations. For instance, after gener-
ating iPSCs from fibroblasts of ALS
patients (Dimos et al., 2008), MNs from
these ALS patient-specific iPSCs wereused for validating potential candidate
drugs and identifying their mechanisms
of action (Egawa et al., 2012).
In this issue of Cell Stem Cell, Yang
et al. (2013) provide a conceptually novel
strategy to discover drugs for treatment
of ALS. In their study, the authors diff-
erentiated mouse embryonic stem cells
(ESCs) carrying either wild-type or mutant
human SOD1 and obtained large number
of MNs. Because other studies found that
trophic factor withdrawal causes signifi-
cant death (around 80%) of MNs carrying
wild-type or human mutant SOD1 (Kieran
et al., 2008), Rubin and colleagues devel-
oped an assay based on this paradigm
and screened approximately 5,000 small
molecules to identify compounds that
prevent cell death of their mouse-ESC-
derived MNs (Yang et al., 2013). The use
of MNs bearing human wild-type or
mutant SOD1 resulted in identification of
22 compounds that showed significant
protective effects. Primary hit from this
screen included compounds such as
inhibitors of apoptosis, a matrix meta-
lloprotease (MMP) inhibitor with agonist
activity at cannabinoid receptors, and a
calpain inhibitor. These compounds
have been previously reported to have
effects in ALS mice models, providing
useful validation of their screen.
Among the remaining compounds,
including several kinase inhibitors, the au-
thors focused on Kenpaullone as a ‘‘hit’’
because it strongly increased survival of
both wild-type and SOD1 mutant MNs.
Although Kenpaullone is a known GSK-3
inhibitor, its capacity to promote MN sur-
vival was significantly greater compared
to other GSK-3 inhibitors tested. The au-
thors then demonstrated that this is dueCell Stem Ceto Kenpaullone’s ability to inhibit HGK,
which acts as an upstream regulator of
a stress-induced neuronal cell death
signal through a Tak1-MKK4-JNK-c-Jun
pathway. Because CHIR99021 (another
GSK-3 inhibitor tested here) could not
rescue MN death in this experimental
setting, HGK could be considered a new
therapeutic target for further drug discov-
ery. Whether inhibition of HGK alone is
effective in preventing MN death, or
whether it requires concurrent inhibition
of GSK-3, requires additional investiga-
tion. In addition to Kenpaullone’s effect
on cell survival, it preserves morphology
and electrophysiological activity even
after long-term treatment, which suggests
additional corrective benefits to MNs
upon chronic treatment.
The authors then extended their valida-
tion of Kenpaullone to human MNs. They
found that Kenpaullone promotes survival
of human ESC (hESC)-derived MNs, as
well as MNs harboring SOD1 mutations
from patient-specific iPSCs. More impor-
tantly, Kenpaullone can prevent death of
MNs carrying mutations in TDP-43,
another major genetic defect found in
congenital ALS (Robberecht and Philips,
2013). Intriguingly, the authors also tested
the effects of olesoxime and dexprami-
pexole. These compounds appeared
promising in mouse studies but did not
fare well in clinical trials (Cudkowicz
et al., 2011; Robberecht and Philips,
2013). Compellingly, these compounds
were not successful in rescuing death of
MNs carrying human SOD1 mutations.
This finding is a powerful example of ‘‘pre-
clinical testing in a dish.’’ Such preliminary
screening steps can potentially save a
huge amount of resources and acceleratell 12, June 6, 2013 ª2013 Elsevier Inc. 633
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Previewsdrug discovery by excluding ineffective
drugs before they proceed to clinical
trials.
One fascinating effect of Kenpaullone
is its ability to rescue cell death of MNs
carrying mutations not only in SOD1 but
also in TDP-43. It remains to be seen
whether Kenpaullone has similar effects
on MNs harboring other ALS-specific mu-
tations, such as C9orf72 (Robberecht and
Philips, 2013), or MNs from patients with
sporadic ALS. If Kenpaullone can rescue
MNs with distinct causative mutations, it
may also act positively on other types of
afflicted neurons in ALS patients. How-
ever, the mechanism behind the effects
of Kenpaullone on MNs carrying distinct
disease-inducing mutations needs to be
clarified. It is possible that a compound
with these pleiotropic effects was re-
vealed due to the design of the primary
screen, as the trophic factor withdrawal
assay may not reflect a primary cause of
MN death in ALS.
ESC- and iPSC-based screens such as
the one performed by Yang et al. require
relatively pure populations of the cell
type of interest. Here, Yang et al. show
MN differentiation efficacy of 30%
50%, a significant improvement over pre-
vious efforts (Wichterle et al., 2002). They
attempt to obtain MN cultures with even
higher purity after primary screening by
Ara-C treatment to kill mitotic cells
and fluorescence-activated cell sorting
(based on GFP expression of the SOD1
transgene). Despite these efforts, the
non-MN population in primary screening
may mask true effects or cause artifacts,
and we cannot exclude the possibility634 Cell Stem Cell 12, June 6, 2013 ª2013 Ethat any of the 22 primary hit compounds
might act indirectly to promote neuronal
survival. It is well known that deriving
pure MN populations from iPSCs is chal-
lenging, and the issues described above
emphasize the importance of developing
more-efficient MN differentiation proto-
cols for use in divergent applications.
As mentioned by the authors (Yang
et al., 2013), the real value of stem-cell-
based screening is the identification of
relevant hit compounds suitable for mov-
ing into animal models of disease for proof
of efficacy. Complex live-animal models
provide further practical difficulties, such
as stability of the compounds, toxicity,
pharmacokinetic properties, and ability
to penetrate the blood-brain barrier,
which must be overcome for initial hits to
show translational potential. Because
other compounds from recent drug
screening efforts using patient-specific
hiPSCs (Choi et al., 2013; Lee et al.,
2012) have not been tested in any in vivo
studies, it will be interesting to see
whether the hit compounds found from
all of these stem-cell-based screening
approaches exhibit positive results in an-
imal models, as well as in clinical tests,
in the near future.
In summary, Yang et al. (2013) showed
the possibility of customized drug valida-
tion using patient-specific iPSCs. This is
one of the best examples of personalized
medicine, particularly from the perspec-
tive of drug discovery, for a disease with
different genetic mutations. While this is
the first trial to identify candidate ALS
therapeutic agents using stem cells,
which could result in discovering novellsevier Inc.ALS-relevant drugs, the future is bright
for targeted drug screening in a variety
of diseases that require otherwise-limited
cell populations.REFERENCES
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